---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-26-000007"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:56:11.573148+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q4 GAAP operating loss $118.9M; non-GAAP EPS down to $2.51 from $2.90

## Summary
- Q4 GAAP operating loss $118.9M vs income $58.4M YoY; gross margin down 140bps to 49.8%.
- Q4 non-GAAP operating income $83.0M (down 10% YoY); non-GAAP EPS $2.51 vs $2.90.
- Full-year non-GAAP operating income $311.6M vs $331.3M; EPS $9.92 vs $10.31.
- Q4 GAAP net income $720.0M vs $715.8M loss YoY driven by equity investment fair value changes.
- CEO cites geopolitical uncertainty and academic funding pressure; Stilla acquisition integrated.

## SEC filing metadata
- accession: 0000012208-26-000007
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220826000007/0000012208-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220826000007/bio-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-26-000007
- JSON: https://secwatch.observer/filing/0000012208-26-000007.json
- Plain text: https://secwatch.observer/filing/0000012208-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.